- Home
- WRLD vs NUVB Comparison
WRLD vs NUVB Comparison
Compare WRLD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- NUVB
- Stock Information
- Founded
- WRLD 1962
- NUVB 2018
- Country
- WRLD United States
- NUVB United States
- Employees
- WRLD N/A
- NUVB N/A
- Industry
- WRLD Finance: Consumer Services
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- NUVB Health Care
- Exchange
- WRLD Nasdaq
- NUVB Nasdaq
- Market Cap
- WRLD 859.5M
- NUVB 837.0M
- IPO Year
- WRLD 1991
- NUVB N/A
- Fundamental
- Price
- WRLD $173.01
- NUVB $3.89
- Analyst Decision
- WRLD
- NUVB Strong Buy
- Analyst Count
- WRLD 0
- NUVB 6
- Target Price
- WRLD N/A
- NUVB $8.00
- AVG Volume (30 Days)
- WRLD 40.7K
- NUVB 5.9M
- Earning Date
- WRLD 10-24-2025
- NUVB 11-05-2025
- Dividend Yield
- WRLD N/A
- NUVB N/A
- EPS Growth
- WRLD 10.95
- NUVB N/A
- EPS
- WRLD 14.92
- NUVB N/A
- Revenue
- WRLD $567,706,032.00
- NUVB $14,355,000.00
- Revenue This Year
- WRLD N/A
- NUVB $332.80
- Revenue Next Year
- WRLD $3.55
- NUVB $360.12
- P/E Ratio
- WRLD $11.78
- NUVB N/A
- Revenue Growth
- WRLD 0.80
- NUVB 900.35
- 52 Week Low
- WRLD $104.99
- NUVB $1.54
- 52 Week High
- WRLD $177.25
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- WRLD 56.58
- NUVB 83.37
- Support Level
- WRLD $165.28
- NUVB $2.87
- Resistance Level
- WRLD $174.51
- NUVB $3.08
- Average True Range (ATR)
- WRLD 4.92
- NUVB 0.22
- MACD
- WRLD 0.41
- NUVB 0.08
- Stochastic Oscillator
- WRLD 82.66
- NUVB 86.52
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.